Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions.
By J. Coppinger, G. Cagney, S. Toomey, T. Kislinger, O. Belton, James P. McRedmond, D. Cahill, Andrew Emili, D. Fitzgerald, P. Maguire. Blood, 2004
877 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Hematology, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/36ee9bf7f3a8455809deb60a450fdc261f5c3400
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
In Hematology
Citations in the corpus
- Cytokines in atherosclerosis: pathogenic and regulatory pathways. (2006, neutral): “TNF- (26, 35, 585, 676) IL-1 (611) IL-2 (214) IL-3 (mRNA expression) (86) IL-6 (586, 618) IL-8 (CXCL8) (22, 586, 718) IL-10 (441, 687) IL-12 (687) IL-15 (289, 750) IL-18 (228, 435) IFN- (214, 267) Oncostatin M (476) TGF- 1, TGF- 2, TGF- 3 (58, 214) Activin A, a member of the TGF- superfamily (191) C”
- Platelet secretion: From haemostasis to wound healing and beyond (2015, background): “example Factors V [3] andXIII [4,5]), and other components that regulate coagulation such as polyphosphates [6,7] and prothrombin [8].”
- Contribution of platelets to tumour metastasis (2011, background): “These factors are anti-angiogenic (such as angiopoietin 1 (ANGPT1; also known ANG1), sphingosine 1-phosphate (S1P), serotonin, thrombospondin 1 (THBS1)); or are pro-angiogenic (such as VEGFA, epidermal growth factor (EGF), basic fibroblast growth factor (bFGF; also known as FGF2)); or function as cy”